Back to Search Start Over

Oxidative stress biomarkers for fetal growth restriction in umbilical cord blood: A scoping review.

Authors :
Blok EL
Burger RJ
Bergeijk JEV
Bourgonje AR
Goor HV
Ganzevoort W
Gordijn SJ
Source :
Placenta [Placenta] 2024 Sep 02; Vol. 154, pp. 88-109. Date of Electronic Publication: 2024 Jun 24.
Publication Year :
2024

Abstract

Fetal growth restriction and underlying placental insufficiency are associated with increased oxidative stress. Current diagnostics fail to identify all growth restricted fetuses and newborns, due to focus on small size. This scoping review aims to summarize the available evidence on usefulness of cord blood oxidative stress biomarkers for identification of growth restricted newborns in need of monitoring and support because of associated health risks. MEDLINE and EMBASE were searched from inception to May 2024. Studies were included if oxidative stress biomarkers were measured in cord blood collected immediately after delivery in newborns suspected to be growth restricted. Biomarkers were categorized based on the origin and/or biological function and their interrelationships. Oxidative stress was determined for each individual biomarker and category. Literature search identified 78 studies on 39 different biomarkers, with a total of 2707 newborns with suspected growth restriction, and 4568 controls. Total oxidant/antioxidant status, catalase, glutathione, ischemia-modified albumin, and nucleated red blood cells were most consistently associated with suspected growth restriction. Reactive oxygen species/reactive nitrogen species, factors in their production, antioxidant enzymes, non-enzymatic antioxidants, and products of oxidative stress were not consistently associated. This review collates the evidence of associations between cord blood oxidative stress biomarkers and growth restriction. Total oxidant/antioxidant status, catalase, glutathione, ischemia-modified albumin, and nucleated red blood cells could potentially be candidates for developing a cord blood diagnostic tool for future clinical use.<br />Competing Interests: Declaration of competing interest WG reports holding government funding (ZonMW 843002825) and free of charge test kits from Roche Diagnostics. SJG reports holding government funding (ZonMW 852002034) and free of charge test kits from Roche Diagnostics. ARB and HvG received a research grant from Janssen Research & Development LLC, outside the submitted work. The other authors report no declarations of interest.<br /> (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Details

Language :
English
ISSN :
1532-3102
Volume :
154
Database :
MEDLINE
Journal :
Placenta
Publication Type :
Academic Journal
Accession number :
38943922
Full Text :
https://doi.org/10.1016/j.placenta.2024.06.018